Semma Therapeutics
New class of regenerative medicine therapies couples its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system.
Launch date
Market cap
-
Enterprise valuation
€864m (Public information from Sep 2019)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$44.0m | Series A | ||
$5.0m | Grant | ||
N/A | Late VC | ||
| N/A | $114m | Series B | |
$950m Valuation: $950m | Acquisition | ||
| Total Funding | €148m | ||
